Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Tumor tissue protein signatures reflect histological grade of breast cancer

Author:
  • Petter Skoog
  • Mattias Ohlsson
  • Mårten Fernö
  • Lisa Rydén
  • Carl Borrebaeck
  • Christer Wingren
Publishing year: 2017-06-26
Language: English
Pages:
Publication/Series: PLoS ONE
Document type: Journal article
Publisher: Public Library of Science

Abstract english

Histological grade is one of the most commonly used prognostic factors for patients diagnosed with breast cancer. However, conventional grading has proven technically challenging, and up to 60% of the tumors are classified as histological grade 2, which represents a heterogeneous cohort less informative for clinical decision making. In an attempt to study and extend the molecular puzzle of histologically graded breast cancer, we have in this pilot project searched for additional protein biomarkers in a new space of the proteome. To this end, we have for the first time performed protein expression profiling of breast cancer tumor tissue, using recombinant antibody microarrays, targeting mainly immunoregulatory proteins. Thus, we have explored the immune system as a disease-specific sensor (clinical immunoproteomics). Uniquely, the results showed that several biologically relevant proteins reflecting histological grade could be delineated. In more detail, the tentative biomarker panels could be used to i) build a candidate model classifying grade 1 vs. grade 3 tumors, ii) demonstrate the molecular heterogeneity among grade 2 tumors, and iii) potentially re-classify several of the grade 2 tumors to more like grade 1 or grade 3 tumors. This could, in the long-term run, lead to improved prognosis, by which the patients could benefit from improved tailored care.
Histological grade is one of the most commonly used prognostic factors for patients diagnosed with breast cancer. However, conventional grading has proven technically challenging, and up to 60% of the tumors are classified as histological grade 2, which represents a heterogeneous cohort less informative for clinical decision making. In an attempt to study and extend the molecular puzzle of histologically graded breast cancer, we have in this pilot project searched for additional protein biomarkers in a new space of the proteome. To this end, we have for the first time performed protein expression profiling of breast cancer tumor tissue, using recombinant antibody microarrays, targeting mainly immunoregulatory proteins. Thus, we have explored the immune system as a disease-specific sensor (clinical immunoproteomics). Uniquely, the results showed that several biologically relevant proteins reflecting histological grade could be delineated. In more detail, the tentative biomarker panels could be used to i) build a candidate model classifying grade 1 vs. grade 3 tumors, ii) demonstrate the molecular heterogeneity among grade 2 tumors, and iii) potentially re-classify several of the grade 2 tumors to more like grade 1 or grade 3 tumors. This could, in the long-term run, lead to improved prognosis, by which the patients could benefit from improved tailored care

Keywords

  • Immunology
  • Cancer and Oncology
  • Breast Cancer
  • Histology
  • Biomarkers
  • Enzyme-linked immunoassays
  • Microarrays
  • Breast tumors
  • Recombinant proteins
  • Antibodies

Other

Published
  • Personalized Breast Cancer Treatment
  • Breast Cancer Surgery
  • The Liquid Biopsy and Tumor Progression in Breast Cancer
  • Artificial Intelligence in CardioThoracic Sciences (AICTS)
  • ISSN: 1932-6203
Carl Borrebaeck
E-mail: carl.borrebaeck [at] immun.lth.se

Professor

Department of Immunotechnology

90

Director

Create Health

+46 46 222 96 13

90